{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:34:28Z","timestamp":1792809268935,"version":"4.5.0"},"reference-count":123,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Combined hormonal contraception (CHC) are short-acting, reversible methods containing both estrogen and progestin. Available CHC methods include combined oral contraceptives, transdermal patches, and vaginal rings. The combined oral contraceptive remains the most commonly used contraceptive method in the United States. The general principles of CHC will be reviewed, including mechanism of action and effectiveness. Unless otherwise stated, these principles apply to all CHCs. When discussing clinical studies and specific considerations related only to pills, patches, or rings, the method(s) will be specified. Words that specify sex are used when discussing studies in which sex was specified.<\/jats:p>","DOI":"10.1097\/grf.0000000000000634","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T10:00:12Z","timestamp":1621850412000},"page":"721-738","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Hormonal Contraception: Systemic Estrogen and Progestin Preparations"],"prefix":"10.1097","volume":"64","author":[{"given":"Nisha","family":"Verma","sequence":"first","affiliation":[{"name":"Department of GYN\/OB, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Cwiak","sequence":"additional","affiliation":[{"name":"Department of GYN\/OB, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Kaunitz","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.contraception.2015.03.001","article-title":"Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial","volume":"91","author":"Seidman","year":"2015","journal-title":"Contraception"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1093\/humrep\/deh493","article-title":"Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study","volume":"19","author":"Duijkers","year":"2004","journal-title":"Hum Reprod"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0015-0282(03)00556-9","article-title":"Ortho Evra\/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error","volume":"80","author":"Pierson","year":"2003","journal-title":"Fertil Steril"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.contraception.2010.06.006","article-title":"Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability","volume":"82","author":"Lewis","year":"2010","journal-title":"Contraception"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.contraception.2012.09.034","article-title":"Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system","volume":"87","author":"Natavio","year":"2013","journal-title":"Contraception"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.contraception.2012.05.004","article-title":"Comparison of cervical mucus of 24\/4 vs. 21\/7 combined oral contraceptives","volume":"86","author":"Steward","year":"2012","journal-title":"Contraception"},{"key":"R8-20250512","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","volume":"7","author":"Arowojolu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.contraception.2012.12.011","article-title":"Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment","volume":"87","author":"Stanczyk","year":"2013","journal-title":"Contraception"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/jwh.2013.4320","article-title":"Efficacy and safety of a combined oral contraceptive containing estradiol valerate\/dienogest: results from a clinical study conducted in North America","volume":"23","author":"Nelson","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1517\/14656561003724713","article-title":"Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest","volume":"11","author":"Jensen","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11591200-000000000-00000","article-title":"Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate\/dienogest versus ethinylestradiol\/levonorgestrel","volume":"11","author":"Klipping","year":"2011","journal-title":"Drugs R D"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","article-title":"Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)","volume":"94","author":"Apter","year":"2016","journal-title":"Contraception"},{"key":"R14-20250512","first-page":"476","article-title":"Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study","volume":"20","author":"Duijkers","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol","volume":"95","author":"Kluft","year":"2017","journal-title":"Contraception"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.contraception.2020.05.017","article-title":"Oral contraceptive generations\u2014time to stop using a marketing myth to define nomenclature","volume":"102","author":"Creinin","year":"2020","journal-title":"Contraception"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/humupd\/dmt038","article-title":"The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis","volume":"20","author":"Zimmerman","year":"2014","journal-title":"Hum Reprod Update"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ogc.2015.07.007","article-title":"Does the progestogen used in combined hormonal contraception affect venous thrombosis risk?","volume":"42","author":"Han","year":"2015","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.contraception.2014.01.023","article-title":"Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives","volume":"89","author":"Dinger","year":"2014","journal-title":"Contraception"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.contraception.2018.11.009","article-title":"An in-depth analysis of the use of shared decision making in contraceptive counseling","volume":"99","author":"Chen","year":"2019","journal-title":"Contraception"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2015.10.007","article-title":"Efficacy and safety of a 21\/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol","volume":"93","author":"Kroll","year":"2016","journal-title":"Contraception"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1001\/jama.285.18.2347","article-title":"Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial","volume":"285","author":"Audet","year":"2001","journal-title":"JAMA"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2006.07.004","article-title":"Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone","volume":"74","author":"Ahrendt","year":"2006","journal-title":"Contraception"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40834-018-0064-y","article-title":"Return of fertility after discontinuation of contraception: a systematic review and meta-analysis","volume":"3","author":"Girum","year":"2018","journal-title":"Contracept Reprod Med"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1093\/humrep\/17.10.2594","article-title":"Ovarian function with a novel combined contraceptive vaginal ring","volume":"17","author":"Mulders","year":"2002","journal-title":"Hum Reprod"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"100038","DOI":"10.1016\/j.conx.2020.100038","article-title":"Beyond safety and efficacy: sexuality-related priorities and their associations with contraceptive method selection","volume":"2","author":"Higgins","year":"2020","journal-title":"Contracept X"},{"key":"R30-20250512","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","article-title":"Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women","volume":"81","author":"Westhoff","year":"2010","journal-title":"Contraception"},{"issue":"suppl 2","key":"R31-20250512","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0015-0282(01)03275-7","article-title":"Contraceptive efficacy and cycle control with the Ortho Evra\/Evra transdermal system: the analysis of pooled data","volume":"77","author":"Zieman","year":"2002","journal-title":"Fertil Steril"},{"key":"R32-20250512","first-page":"CD008452","article-title":"Hormonal contraceptives for contraception in overweight or obese women","volume":"8","author":"Lopez","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R33-20250512","doi-asserted-by":"crossref","first-page":"263.e1","DOI":"10.1016\/j.ajog.2009.03.017","article-title":"Oral contraceptive effectiveness according to body mass index, weight, age, and other factors","volume":"201","author":"Dinger","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R34-20250512","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.contraception.2015.07.016","article-title":"Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis","volume":"92","author":"Yamazaki","year":"2015","journal-title":"Contraception"},{"key":"R35-20250512","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/AOG.0b013e31820095a2","article-title":"Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen","volume":"117","author":"Dinger","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R36-20250512","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.contraception.2011.08.001","article-title":"Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive","volume":"85","author":"Westhoff","year":"2012","journal-title":"Contraception"},{"key":"R37-20250512","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.contraception.2011.09.019","article-title":"Predictors of noncompliance in an oral contraceptive clinical trial","volume":"85","author":"Westhoff","year":"2012","journal-title":"Contraception"},{"key":"R38-20250512","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"},{"key":"R39-20250512","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.contraception.2016.10.010","article-title":"Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review","volume":"95","author":"Dragoman","year":"2017","journal-title":"Contraception"},{"key":"R40-20250512","doi-asserted-by":"crossref","first-page":"39.e1","DOI":"10.1016\/j.ajog.2012.04.022","article-title":"Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women","volume":"207","author":"Westhoff","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R41-20250512","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.contraception.2012.12.001","article-title":"Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women","volume":"87","author":"Dragoman","year":"2013","journal-title":"Contraception"},{"key":"R42-20250512","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1528-1167.2010.02917.x","article-title":"Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding","volume":"52","author":"Davis","year":"2011","journal-title":"Epilepsia"},{"key":"R43-20250512","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(01)00305-9","article-title":"Lamotrigine plasma levels reduced by oral contraceptives","volume":"47","author":"Sabers","year":"2001","journal-title":"Epilepsy Res"},{"key":"R44-20250512","first-page":"565","article-title":"International notes valproic acid and spina bifida: a preliminary report\u2014France","volume":"31","year":"1982","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R45-20250512","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.contraception.2016.07.010","article-title":"Co-administration of St. John\u2019s wort and hormonal contraceptives: a systematic review","volume":"94","author":"Berry-Bibee","year":"2016","journal-title":"Contraception"},{"issue":"pt 1","key":"R46-20250512","first-page":"853","article-title":"Drug interactions between oral contraceptives and antibiotics","volume":"98","author":"Dickinson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R47-20250512","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R48-20250512","first-page":"1","article-title":"U.S. selected practice recommendations for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R49-20250512","doi-asserted-by":"crossref","first-page":"151268","DOI":"10.1016\/j.semperi.2020.151268","article-title":"Contraception for high risk patients","volume":"44","author":"Cwiak","year":"2020","journal-title":"Semin Perinatol"},{"key":"R50-20250512","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0010-7824(02)00326-8","article-title":"Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills","volume":"66","author":"Lara-Torre","year":"2002","journal-title":"Contraception"},{"key":"R51-20250512","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.contraception.2005.05.009","article-title":"Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods","volume":"72","author":"Murthy","year":"2005","journal-title":"Contraception"},{"key":"R52-20250512","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.AOG.0000164483.13326.59","article-title":"Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive","volume":"106","author":"Westhoff","year":"2005","journal-title":"Obstet Gynecol"},{"key":"R53-20250512","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.contraception.2012.08.025","article-title":"Blood pressure measurement prior to initiating hormonal contraception: a systematic review","volume":"87","author":"Tepper","year":"2013","journal-title":"Contraception"},{"key":"R54-20250512","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/bmj.313.7065.1127","article-title":"Factor V Leiden: should we screen oral contraceptive users and pregnant women?","volume":"313","author":"Vandenbroucke","year":"1996","journal-title":"BMJ"},{"key":"R55-20250512","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1783\/147118910791749425","article-title":"Oral Contraceptives and Venous Thromboembolism. Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009","volume":"36","author":"Reid","year":"2010","journal-title":"J Fam Plann Reprod Health Care"},{"key":"R56-20250512","first-page":"Cd011054","article-title":"Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke","volume":"2015","author":"Roach","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-20250512","doi-asserted-by":"crossref","first-page":"412.e1","DOI":"10.1016\/j.ajog.2006.12.015","article-title":"Oral contraceptive discontinuation: do side effects matter?","volume":"196","author":"Westhoff","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"R58-20250512","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.contraception.2009.03.018","article-title":"Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate\/dienogest and ethinyl estradiol\/levonorgestrel","volume":"80","author":"Ahrendt","year":"2009","journal-title":"Contraception"},{"key":"R59-20250512","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0010-7824(01)00208-6","article-title":"Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials","volume":"63","author":"Coney","year":"2001","journal-title":"Contraception"},{"key":"R60-20250512","first-page":"CD003987","article-title":"Combination contraceptives: effects on weight","volume":"1","author":"Gallo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R61-20250512","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13625187.2016.1217327","article-title":"Combined hormonal contraception and its effects on mood: a critical review","volume":"21","author":"Schaffir","year":"2016","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R62-20250512","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/13625187.2012.728643","article-title":"The influence of combined oral contraceptives on female sexual desire: a systematic review","volume":"18","author":"Pastor","year":"2013","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R63-20250512","first-page":"CD003989","article-title":"20 microg versus >20 microg estrogen combined oral contraceptives for contraception","volume":"8","author":"Gallo","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 2","key":"R64-20250512","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0015-0282(01)03264-2","article-title":"A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra\/Evra)","volume":"77","author":"Sibai","year":"2002","journal-title":"Fertil Steril"},{"key":"R65-20250512","first-page":"CD003552","article-title":"Skin patch and vaginal ring versus combined oral contraceptives for contraception","volume":"4","author":"Lopez","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R66-20250512","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.contraception.2004.09.001","article-title":"Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial","volume":"71","author":"Oddsson","year":"2005","journal-title":"Contraception"},{"key":"R67-20250512","first-page":"585","article-title":"Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring","volume":"100","author":"Dieben","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R68-20250512","first-page":"CD004695","article-title":"Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception","volume":"7","author":"Edelman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R69-20250512","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ajog.2006.02.048","article-title":"Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen","volume":"195","author":"Sulak","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R70-20250512","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.AOG.0000199950.64545.16","article-title":"Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?","volume":"107","author":"Edelman","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R71-20250512","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1097\/01.AOG.0000465189.50026.20","article-title":"The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia","volume":"125","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R72-20250512","first-page":"913","article-title":"Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding","volume":"96","author":"Davis","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R73-20250512","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2005.01.021","article-title":"Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception","volume":"121","author":"Urdl","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R74-20250512","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/13625187.2017.1287351","article-title":"Efficacy and side-effects profile of the ethinylestradiol and etonogestrel contraceptive vaginal ring: a systematic review and meta-analysis","volume":"22","author":"Lopez-Picado","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"R75-20250512","first-page":"CD000154","article-title":"Oral contraceptive pill for heavy menstrual bleeding","volume":"4","author":"Farquhar","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R76-20250512","first-page":"CD000154","article-title":"Combined hormonal contraceptives for heavy menstrual bleeding","volume":"2","author":"Lethaby","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R77-20250512","first-page":"253","article-title":"Low-dose combination oral contraceptives use in women with uterine leiomyomas","volume":"54","author":"Orsini","year":"2002","journal-title":"Minerva Ginecol"},{"key":"R78-20250512","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1055\/s-0038-1649813","article-title":"The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH","volume":"74","author":"Foster","year":"1995","journal-title":"Thromb Haemost"},{"key":"R79-20250512","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.contraception.2009.09.014","article-title":"Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review","volume":"81","author":"Zahradnik","year":"2010","journal-title":"Contraception"},{"key":"R80-20250512","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/humrep\/del162","article-title":"Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3mg drospirenone","volume":"21","author":"Milsom","year":"2006","journal-title":"Hum Reprod"},{"key":"R82-20250512","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.fertnstert.2007.08.051","article-title":"Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial","volume":"90","author":"Harada","year":"2008","journal-title":"Fertil Steril"},{"key":"R83-20250512","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0015-0282(03)00794-5","article-title":"Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen","volume":"80","author":"Vercellini","year":"2003","journal-title":"Fertil Steril"},{"key":"R84-20250512","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.contraception.2004.07.010","article-title":"A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms","volume":"71","author":"Sangthawan","year":"2005","journal-title":"Contraception"},{"key":"R85-20250512","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2006.05.012","article-title":"Oral contraceptives and premenstrual symptoms: comparison of a 21\/7 and extended regimen","volume":"195","author":"Coffee","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R86-20250512","first-page":"CD006586","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","volume":"2","author":"Lopez","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R87-20250512","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.contraception.2009.04.014","article-title":"An evidence-based approach to hormonal contraception and headaches","volume":"80","author":"Harris","year":"2009","journal-title":"Contraception"},{"key":"R88-20250512","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.contraception.2010.04.002","article-title":"Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome","volume":"82","author":"De Leo","year":"2010","journal-title":"Contraception"},{"key":"R89-20250512","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"key":"R90-20250512","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","article-title":"Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity","volume":"72","author":"Sullivan","year":"1999","journal-title":"Fertil Steril"},{"key":"R91-20250512","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0029-7844(97)00059-8","article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","volume":"89","author":"Redmond","year":"1997","journal-title":"Obstet Gynecol"},{"issue":"pt 1","key":"R92-20250512","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0190-9622(97)70112-9","article-title":"Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris","volume":"37","author":"Lucky","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"R93-20250512","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMcp054015","article-title":"Clinical practice. Management of menopausal symptoms","volume":"355","author":"Grady","year":"2006","journal-title":"N Engl J Med"},{"key":"R94-20250512","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1210\/jc.2007-0066","article-title":"Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system","volume":"92","author":"Hale","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R96-20250512","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/GME.0000000000000319","article-title":"The North American Menopause Society recommendations for clinical care of midlife women","volume":"21","author":"Shifren","year":"2014","journal-title":"Menopause"},{"key":"R97-20250512","first-page":"CD004143","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R98-20250512","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1056\/NEJMcp0708481","article-title":"Clinical practice. Hormonal contraception in women of older reproductive age","volume":"358","author":"Kaunitz","year":"2008","journal-title":"N Engl J Med"},{"key":"R99-20250512","first-page":"15","article-title":"Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study","volume":"30","author":"Shargil","year":"1985","journal-title":"Int J Fertil"},{"key":"R100-20250512","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet"},{"issue":"suppl 1","key":"R101-20250512","doi-asserted-by":"crossref","first-page":"sI20","DOI":"10.1016\/S0140-6736(97)90007-6","article-title":"Hormones and bones","volume":"349","author":"Rizzoli","year":"1997","journal-title":"Lancet"},{"key":"R102-20250512","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40695-018-0035-0","article-title":"Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status","volume":"4","author":"Beksinska","year":"2018","journal-title":"Womens Midlife Health"},{"key":"R103-20250512","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.contraception.2009.09.011","article-title":"Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study","volume":"81","author":"Massaro","year":"2010","journal-title":"Contraception"},{"key":"R104-20250512","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1093\/humrep\/dei117","article-title":"The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women","volume":"20","author":"Massai","year":"2005","journal-title":"Hum Reprod"},{"key":"R105-20250512","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(98)09044-8","article-title":"Oral-contraceptive use and risk of hip fracture: a case-control study","volume":"353","author":"Micha\u00eblsson","year":"1999","journal-title":"Lancet"},{"key":"R106-20250512","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00006254-200405000-00025","article-title":"Endometrial hyperplasia: a review","volume":"59","author":"Montgomery","year":"2004","journal-title":"Obstet Gynecol Surv"},{"key":"R107-20250512","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/91.13.1131","article-title":"Risk of endometrial cancer following estrogen replacement with and without progestins","volume":"91","author":"Weiderpass","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R108-20250512","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0029-1242998","article-title":"Role of progesterone in endometrial cancer","volume":"28","author":"Kim","year":"2010","journal-title":"Semin Reprod Med"},{"key":"R109-20250512","first-page":"796","article-title":"Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development","volume":"257","year":"1987","journal-title":"JAMA"},{"key":"R110-20250512","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1677\/ERC-10-0076","article-title":"Hormonal contraception and risk of endometrial cancer: a systematic review","volume":"17","author":"Mueck","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"R111-20250512","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2017.4942","article-title":"Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers","volume":"4","author":"Michels","year":"2018","journal-title":"JAMA Oncol"},{"key":"R112-20250512","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11912-018-0747-1","article-title":"Prevention strategies in endometrial carcinoma","volume":"20","author":"MacKintosh","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"R113-20250512","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/94.1.32","article-title":"Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk","volume":"94","author":"Schildkraut","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R114-20250512","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R115-20250512","doi-asserted-by":"crossref","first-page":"580.e1","DOI":"10.1016\/j.ajog.2017.02.002","article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners\u2019 Oral Contraception Study","volume":"216","author":"Iversen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R116-20250512","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1054\/bjoc.2000.1622","article-title":"Oral contraceptives and colorectal cancer risk: a meta-analysis","volume":"84","author":"Fernandez","year":"2001","journal-title":"Br J Cancer"},{"key":"R117-20250512","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R118-20250512","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R119-20250512","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"R120-20250512","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"Morch","year":"2017","journal-title":"N Engl J Med"},{"key":"R121-20250512","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N Engl J Med"},{"key":"R122-20250512","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception"},{"key":"R123-20250512","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0091270006297919","article-title":"Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive","volume":"47","author":"Devineni","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R124-20250512","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.contraception.2011.10.006","article-title":"Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial","volume":"85","author":"Archer","year":"2012","journal-title":"Contraception"},{"key":"R125-20250512","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R126-20250512","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1016\/S2214-109X(19)30265-7","article-title":"Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials","volume":"7","author":"Archer","year":"2019","journal-title":"Lancet Glob Health"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T11:11:00Z","timestamp":1747048260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000634","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,24]]}}}